Cattaneo, D., Fusi, M., Galli, L., Genovese, C., Giorgi, R., Matone, M., Merli, S., Colaneri, M., and Gori, A.: Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/ periprosthetic joint infections, Antimicrob. Agents Ch., 68, e00023-24, https://doi.org/10.1128/aac.00023-24, 2024.
Cojutti, P. G., Rinaldi, M., Gatti, M., Tedeschi, S., Viale, P., and Pea, F.: Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept, Int. J. Antimicrob. Agents, 58, 106445, https://doi.org/10.1016/j.ijantimicag.2021.106445, 2021.
Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., and Baldassarre, J.: Extended-duration dosing and distribution of dalbavancin into bone and articular tissue, Antimicrob. Agents Ch., 59, 1849–1855, https://doi.org/10.1128/AAC.04550-14, 2015.
Dunne, M. W., Puttagunta, S., Giordano, P., Krievins, D., Zelasky, M., and Baldassarre, J.: A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection, Clin. Infect. Dis., 62, 545–551, https://doi.org/10.1093/cid/civ982, 2016.
Esposito, S., Pagliano, P., De Simone, G., Guarino, A., Pan, A., Brambilla, P., Mastroianni, C., Lichtner, M., Brugnaro, P., Carretta, A., Santantonio, T., Brindicci, G., Carrega, G., Montagnani, F., Lapadula, G., Spolti, A., Luzzati, R., Schiaroli, E., Scaglione, V., Pallotto, C., Tacconi, D., Quintieri, F., and Trecarichi, E.: In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry, Infection, 52, 1297–1306, https://doi.org/10.1007/s15010-024-02176-2, 2024.
Gatti, M., Andreoni, M., Pea, F., and Viale, P.: Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs, Drug Des. Devel. Ther., 15, 3349–3378, https://doi.org/10.2147/DDDT.S313756, 2021.
Hanssen, J. L. J., van der Wal, R. J. P., van der Linden, H. M. J., van Prehn, J., Scheper, H., and de Boer, M. G. J.: Dosing and treatment duration of suppressive antimicrobial therapy in orthopedic implant infections: a cohort study, J. Bone Jt. Infect., 9, 149–159, https://doi.org/10.5194/jbji-9-149-2024, 2024.
Horne, M., Woolley, I., and Lau, J. S. Y.: The Use of Long-term Antibiotics for Suppression of Bacterial Infections, Clin. Infect. Dis., 79, 848–854, https://doi.org/10.1093/cid/ciae302, 2024.
Malabarba, A. and Goldstein, B. P.: Origin, structure, and activity in vitro and in vivo of dalbavancin, J. Antimicrob. Chemoth., 55, ii15–ii20, https://doi.org/10.1093/jac/dki005, 2005.
Martín, L. B., Fernández, M. M., Ruiz, J. M. P., Lafont, M. O., Paredes, L. Á., Rodríguez, M. Á. M., Regueras, M. F., Morón, M. Á. M., and Lobón, G. M.: Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study, Revista Espanola de Quimioterapia, 32, 532–538, 2019.
Mendes, R. E., Castanheira, M., Farrell, D. J., Flamm, R. K., Sader, H. S., and Jones, R. N.: Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13): Table 1, J. Antimicrob. Chemoth., 71, 276–278, https://doi.org/10.1093/jac/dkv303, 2016.
Rappo, U., Puttagunta, S., Shevchenko, V., Shevchenko, A., Jandourek, A., Gonzalez, P. L., Suen, A., Mas Casullo, V., Melnick, D., Miceli, R., Kovacevic, M., De Bock, G., and Dunne, M. W.: Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety, Open Forum Infect. Dis., 6, ofy331, https://doi.org/10.1093/ofid/ofy331, 2019a.
Rappo, U., Dunne, M. W., Puttagunta, S., Baldassarre, J. S., Su, S., Desai-Krieger, D., and Inoue, M.: Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion, Antimicrob. Agents Ch., 63, 11, https://doi.org/10.1128/AAC.01024-19, 2019b.
Senneville, E., Cuervo, G., Gregoire, M., Hidalgo-Tenorio, C., Jehl, F., Miro, J. M., Seaton, A., Söderquist, B., Soriano, A., Thalhammer, F., and Pea, F.: Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel, Int. J. Antimicrob. Agents, 62, 106960, https://doi.org/10.1016/j.ijantimicag.2023.106960, 2023.
Silva, V., Miranda, C., Bezerra, M., Antão, H. S., Guimarães, J., Prada, J., Pires, I., Maltez, L., Pereira, J. E., Capelo, J. L., Igrejas, G., and Poeta, P.: Anti-biofilm activity of dalbavancin against methicillin-resistant
Staphylococcus aureus (MRSA) isolated from human bone infection, J. Chemotherapy, 33, 469–475, https://doi.org/10.1080/1120009X.2021.1911518, 2021.
Söderquist, B.: Trough levels of dalbavancin during long-term treatment of prosthetic joint infections, in: EBJIS2024, 42nd Annual Meeting of the European Bone & Joint Infection Society, 26–28 September 2024, Barcelona, Spain, https://doi.org/10.1302/1358-992X.2024.19.022, 2024.
Weber, R. E., Fleige, C., Layer, F., Neumann, B., Kresken, M., and Werner, G.: Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium, Antibiotics, 10, 915, https://doi.org/10.3390/antibiotics10080915, 2021.
Wouthuyzen-Bakker, M., Nijman, J. M., Kampinga, G. A., Assen, S. v., and Jutte, P. C.: Efficacy of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection, J. Bone Joint Infect., 2, 77–83, https://doi.org/10.7150/jbji.17353, 2017.
Wunsch, S., Krause, R., Valentin, T., Prattes, J., Janata, O., Lenger, A., Bellmann-Weiler, R., Weiss, G., and Zollner-Schwetz, I.: Multicenter clinical experience of real life Dalbavancin use in gram-positive infections, Int. J. Infect. Dis., 81, 210–214, https://doi.org/10.1016/j.ijid.2019.02.013, 2019.